Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study.
Saved in:
| Title: | Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study. |
|---|---|
| Authors: | Facheris, Paola1,2 (AUTHOR) Paola.facheris91@gmail.com, Piscazzi, Francesco1,3 (AUTHOR), Fiorillo, Giovanni1,3,4 (AUTHOR), Valenti, Mario1,3 (AUTHOR), Costanzo, Antonio1,3 (AUTHOR), Borroni, Riccardo G.1,3 (AUTHOR) |
| Source: | Dermatology & Therapy. Jun2026, Vol. 16 Issue 6, p3027-3036. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
